EnGeneIC Named One of Science Meets Business Top 25 Australian Research and Development Spin-Off Companies
Mar 10, 2016, 08:30 ET from EnGeneIC Ltd.
NEW YORK and SYDNEY, March 10, 2016 /PRNewswire/ -- EnGeneIC Ltd., a clinical stage biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced today that Science Meets Business, produced by Refraction Media in collaboration with Australia's Cooperative Research Centres (CRC) Association, has honored the Company as one of Australia's 25 most innovative research and development spin-off companies. The list, published in Science Meets Business's partner magazine, KnowHow, was distributed at the CRC Association conference, The Business of Innovative 2016, which occurred March 7-9 at the Brisbane Convention and Exhibition Centre.
EnGeneIC received the Science Meets Business Top 25 Australian R&D spin-off companies award in recognition of the Company's proprietary EDV™ nanocell technology platform, which is a powerful nanoparticle drug, siRNA or miRNA delivery system designed to directly target and effectively kill tumor cells with minimal toxicity, while at the same time stimulate the immune system's natural anti-tumor response. Developed entirely in house by the founders and Joint CEOs, Drs. Himanshu Brahmbhatt and Jennifer MacDiarmid, the Company holds more than 260 patents worldwide to support the technology and does not rely on the licensing of any technology from a third party.
Dr. MacDiarmid commented, "We are honored to receive recognition as one of the top 25 Australian companies that have successfully moved their R&D beyond the lab, as well as to have our EDV nanocells identified as a technology with the potential to change the overall treatment of cancer. This award is especially motivating as EnGeneIC seeks exciting business and financial opportunities to support the Company's rapidly advancing clinical programs."
The Top 25 Science Meets Business R&D spin off companies was written by Refraction Media in consultation with universities and funding bodies, and supported by data from Thomson Reuters. The research compiled by Refraction Media was judged by a panel comprising of: Dr. Peter Riddles, biotechnology expert and director on many start-up enterprises; Dr. Anna Lavelle, CEO and Executive Director of AusBiotech; and Dr. Tony Peacock, Chief Executive of the CRC Association. The panel considered the following: total market value, annual turnover, patents awarded and cited, funding and investment, growth year-on-year, social value, overseas expansion and major partnerships.
About EnGeneIC and the EDV™ Nanocell Technology
EnGeneIC is a clinical stage biopharmaceutical company focused on developing its proprietary bacterially-derived EDV™ nanocells as a powerful nanoparticle drug, siRNA, or miRNA delivery platform designed to directly target and effectively kill tumor cells with minimal toxicity, while simultaneously stimulating the immune system's natural anti-tumor response. Intravenously injected EDV™ nanocells exit the leaky vascular system only found within tumors and attach to cancer cells via a specially designed, targeted bi-specific antibody. Once attached, the nanocell is able to enter the tumor cell and deliver a drug, siRNA, or miRNA payload at high concentrations, intracellularly. The EDV™ nanocell platform has shown promising results in early clinical studies and EnGeneIC is currently planning to commence further clinical trials in several cancer indications in Australia and USA.
For more information, please visit www.engeneic.com
U.S. Investor Contact:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
+1-212-375-2664
jdrumm@tiberend.com
U.S. Media Contact:
Tiberend Strategic Advisors, Inc.
Amy S. Wheeler
+1-646-362-5750
awheeler@tiberend.com
Australia Media Contact:
Felicity Moffatt
+61-418-677701
felicity@mdmedia.net.au
SOURCE EnGeneIC Ltd.
RELATED LINKS
Share this article